Pregnancy and Fetal Outcomes Following Exposure to Modafinil and Armodafinil During Pregnancy
Authors:
Open Access
- 1 February 2021
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 181 (2) , 275-277
Abstract
Although results of animal studies have shown reproductive toxic effects with use of modafinil and armodafinil, data on exposure during pregnancy in humans are limited.1,2 The US Provigil/Nuvigil Pregnancy Registry, a postmarketing requirement with data annually reported to the US Food and Drug Administration, was established to evaluate pregnancy and fetal outcomes in individuals who could become pregnant and received these drugs during pregnancy. This report provides results from cumulative data as of February 2019.Keywords
This publication has 5 references indexed in Scilit:
- First-Trimester Pregnancy Exposure to Modafinil and Risk of Congenital MalformationsJAMA, 2020
- Narcolepsy with cataplexy and pregnancy: a case–control studyJournal of Sleep Research, 2017
- Narcolepsy and pregnancy: a retrospective European evaluation of 249 pregnanciesJournal of Sleep Research, 2013
- Prevalence of Congenital Heart Defects in Metropolitan Atlanta, 1998-2005The Journal of Pediatrics, 2008
- Update on overall prevalence of major birth defects--Atlanta, Georgia, 1978-2005.2008